Tenaya Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent in connection with a $75 million SEC-registered at-the-market offering by Tenaya Therapeutics, Inc. of its common stock. Tenaya’s common stock is listed on the Nasdaq Global Select Market under the symbol "TNYA."
Based in South San Francisco, California, Tenaya Therapeutics is a biotechnology company that discovers, develops and delivers curative therapies to address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: gene therapy, cellular regeneration and precision medicine.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Beth LeBow and Henry Hawkins. Partner David R. Bauer and associates David A. Frey and Alexis N. Wallace provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.